Sign in
Stories
Dyadic's Animal-Free Serum Albumin Progress
Share
Biotech Updates and Market Projections
Stem Cell Therapy and Public Offerings
Biopharma Companies Announce Public Offe...
Burning Rock Biotech and Harvard Bioscie...
Domain Therapeutics Strengthens Leadersh...
Overview
API
Dyadic International, a global biotechnology company, has made progress towards commercializing animal-free recombinant serum albumin, positioning itself for growth in the global albumin market. The company will report its second-quarter financial results and host a corporate update conference call on August 9, 2023.
Ask a question
How might the commercialization of animal-free recombinant serum albumin impact the traditional pharmaceutical and biotech industries?
How might the increasing value of the global albumin market influence the adoption and commercialization of animal-free alternatives?
What are the potential implications of Dyadic's proprietary microbial platform technologies for the development of future biopharmaceutical products?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Apr 2023
May 2023
Jun 2023
Jul 2023
Coverage